KAIROS PHARMA, LTD.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | — | $-1.2M | $437.0K |
| FY2023 | — | $-2.1M | $93.0K |
| FY2024 | — | $4.8M | $1.3M |
| FY2025 | — | $6.3M | $4.5M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | — | $-1.2M | $437.0K |
| FY2023 | — | $-2.1M | $93.0K |
| FY2024 | — | $4.8M | $1.3M |
| FY2025 | — | $6.3M | $4.5M |